BRUKINSA - A Powerful Choice in R/R mzl

24-hour inhibition of BTK was maintained at 100% in PBMCs and 94% to 100% in lymph nodes when taken at the recommended total daily dose of 320 mg. The clinical significance of 100% inhibition has not been established.1,2

THE BTK INHIBITOR
FOR R/R mzl DEMONSTRATED
TO PROVIDE COMPLETE
AND SUSTAINED INHIBITION1,2

Deep and sustained responses

Powerful responses with brukinsa regardless of risk factor or MZL subtype1

Response rates
CT-Based
Magnolia
(Study 214)
56
%
orr
study 003
(MZL)
80
%
orr
Response rates
PET-Based
magnolia
(study 214)
67
%
orr

Median follow-up time was 15.7 months for MAGNOLIA (Study 214) and 35.2 months for Study 003.3

Median DOR has not yet been reached.1

The efficacy of BRUKINSA was assessed by IRC in 2 clinical trials that included a total of 88 adult patients with MZL who received at least 1 prior therapy. Study BGB-3111-214 MAGNOLIA (Study 214): N=68, Phase 2, open-label, multicenter, single-arm trial; PET scans were required for response assessment. Study BGB-3111-AU-003 (Study 003): N=20, Phase 1/2, open-label, multicenter, single-arm trial; PET scans were not required for response assessment and the majority of patients were assessed mostly using CT scans.

*Two patients in MAGNOLIA (Study 214, N=68) were not evaluable for efficacy due to central confirmation of MZL transformation to diffuse large B-cell lymphoma.

55 patients were assessed by PET scan, with the remainder assessed by CT scan.


BTK=Bruton’s tyrosine kinase; CI=confidence interval; CT=computed tomography; IRC=independent review committee; ORR=overall response rate; PBMCs=peripheral blood mononuclear cells; PET=positron emission tomography.

Personalized patient support
dedicated to helping patients

A personalized and comprehensive support program designed
to help guide and assist patients, caregivers, and practices.

Simplifying
Access
Educating
Patients
Securing
Support

Healthcare professional resources

Find tools and education to help your practice

Complete
BTK inhibition
Brukinsa Difference
Established
Safety Profile
Safety
Flexible
Dosing
Dosing